A preventative migraine treatment from Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has cleared a major hurdle. Emgality, a once-monthly injectable treatment, has received U.S. Food and Drug Administration approval. The pharmaceutical manufacturer says Emgality will be commercially available shortly and that a Medical Expenditures Panel Survey suggests costs in the U.S. associated with migraine total up to $56 billion a year. The disease affects 30 million adults in the country.
Lilly Bio-Medicines President Christi Shaw says "despite the devastating impact of migraine, only about 10 percent of people living with the disease are currently taking a preventive treatment. For more than two decades, Lilly has recognized this unmet need, and we have worked tirelessly to develop a new option specifically designed for the prevention of migraine. With this approval, we are thrilled to offer a preventive treatment option to adults living with this disease."
Emgality now awaits final approval from the European Commission, which has authority in the European Union. You can connect to more about the treatment’s U.S. approval by clicking here.